News
- March 14, 2024 858 Therapeutics to Present Preclinical Data on ETX-19477 at the AACR 2024 Annual Meeting
- December 20, 2023 858 Therapeutics Expands Leadership Team to Support Transition to the Clinic
- April 5, 2022 858 Therapeutics Expands Board of Directors and Leadership Team
- September 21, 2021 858 Therapeutics Launches with Proven Team and $60 Million Series A Financing
- September 21, 2021 Bristol Myers, Genentech and Celgene bought their old biotechs. Jeffrey Stafford and co. are ready for their next $60M act
- September 21, 2021 After selling to Genentech, the old Jecure team is back at an RNA-focused startup — and more enthusiastic than ever